Chronic kidney disease is a global health problem affecting 10% to 12% of the population. Uremic cardiomyopathy is often characterized by left ventricular hypertrophy, fibrosis, and diastolic dysfunction. Dysregulation of neuregulin-1β signaling in the heart is a known contributor to heart failure. The systemically administered recombinant human neuregulin-1β for 10 days in our 5/6 nephrectomy-induced model of chronic kidney disease alleviated the progression of uremic cardiomyopathy and kidney dysfunction in type 4 cardiorenal syndrome. The currently presented positive preclinical data warrant clinical studies to confirm the beneficial effects of recombinant human neuregulin-1β in patients with chronic kidney disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543921 | PMC |
| http://dx.doi.org/10.1016/j.jacbts.2023.03.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recovery of Myocardial Functions After Kidney Transplantation in Patients with Heart Failure Due to Uremic Cardiomyopathy.
Turk Kardiyol Dern Ars
January 2025
Department of Cardiology, Istanbul Basaksehir Cam and Sakura City Hospital, Basaksehir, Istanbul, Türkiye.
Objective: Although left ventricular hypertrophy frequently accompanies end-stage renal disease, heart failure (HF) with reduced ejection fraction (EF) is also observed in a subset of patients. In those patients kidney transplantation (KT) is generally avoided due to an increased risk of mortality in addition to the risks associated with HF. This prospective study was designed to follow patients with HF who were being prepared for KT.
View Article and Find Full Text PDFThe effects of hemodialysis on the cardiovascular system.
Semin Vasc Surg
December 2024
Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, BCM 390, Houston TX 77030.
Chronic kidney disease and dialysis-dependent end-stage renal disease are increasing in prevalence in the United States. The costs associated with end-stage renal disease management comprise approximately 1% of the federal government's annual budget. Chronic kidney disease and end-stage renal disease cause significant derangements of the cardiac and vascular system.
View Article and Find Full Text PDFMetabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy.
ESC Heart Fail
November 2024
Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Background And Aims: The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
View Article and Find Full Text PDFIncreased Susceptibility of Cardiac Tissue to PM-Induced Toxicity in Uremic Cardiomyopathic Rats Is Linked to Elevated Levels of Mitochondrial Dysfunction.
Environ Toxicol
October 2024
Vascular Biology Lab, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, Tamil Nadu, India.
Patients with chronic kidney disease (CKD) frequently develop uremic cardiomyopathy, characterized by mitochondrial dysfunction as one of its pathologically significant mediators. Given that PM specifically targets cardiac mitochondria, exacerbating toxicity, this study addresses the potential alterations in the severity of PM toxicity in the context of CKD conditions. Female Wistar rats were exposed to PM at a concentration of 250 μg/m daily for 3 h for 21 days after which an adenine-induced CKD model was developed.
View Article and Find Full Text PDFLanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report.
Front Immunol
October 2024
Internal Medicine Department, Fatebenefratelli Hospital, Milan, Italy.
Article Synopsis
- Cardiovascular diseases are the leading cause of death in patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH), often exacerbated by long-term treatments like attenuated androgens that can increase cardiovascular risk.
- A case study of a 56-year-old HAE-C1INH patient with numerous health issues, including kidney impairment and hypertension, showcased a successful transition from traditional androgen therapy to the modern treatment, lanadelumab, starting in 2020.
- After beginning lanadelumab, the patient saw no angioedema attacks, experienced a decrease in cardiovascular risk factors like cholesterol and body mass index, and improved overall health outcomes, indicating this treatment's effectiveness and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!